• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Journal of Pharmaceutical Policy and Practice >Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy
【2h】

Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy

机译：在中低收入国家与劣质药物作斗争：宣传和教学法的重要性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries.Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly “involved” with medicines: regulators, international organizations, journalists, purchasers, prescribers, program managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from research and monitoring programs, and technical concepts should be translated in lay language through communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines needs the participation of all, and can only be successful if grounded in common understanding.
机译：制药生产的全球化并未伴随着全球监管体系的加强和协调。因此，当今全球市场的特点是存在多种标准，中低收入国家的患者面临着接受劣质药物的风险。在首先对此问题发出警报的人中，有一些先锋的人道主义团体，他们有特权看到高收入国家与中低收入国家之间的药品质量差距。这个问题以及一些积极举措的启动，北方和南方之间的药品质量差异仍然很重要，并且没有得到充分解决。为了普及获得质量保证的药物，需要更多的倡导。它应该针对所有与药物“密切相关”的人：监管者，国际组织，记者，购买者，处方者，项目经理，政策制定者，公共卫生参与者和患者。倡导应基于研究和监测计划的证据，技术概念应通过针对所有利益相关者的交流工具以通俗易懂的语言进行翻译。确保普遍获得优质药品的斗争需要所有人的参与，只有在有共同理解的基础上才能成功。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号